Clinical Trial Update: CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CCI-779 in patients with recurrent glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Glioblastoma
• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• CCI-779 (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: COMPLETED